Therefore, targeting HGF/c-Met axis is one of the most promising therapies for HCC (You et al., 2011; Gao et al., 2012, 2017; Goyal et al., 2013; Graveel et al., 2013; Giordano and Columbano, 2014; Blagotinsek and Rozman, 2017). The gene discussed is MET; the disease is hepatocellular carcinoma.